Advertisement

ACE Inhibitors and Angiotensin Receptor Blockers: a New Effective Non-Conventional Approach to Prevent Atrial Fibrillation

  • A. H. Madrid
  • C. Escobar
  • J. M. G. Rebollo
  • I. Marin
  • E. Bernal
  • L. Limón
  • S. Nannini
  • J. Peng
  • C. Moro
Conference paper

Abstract

Atrial fibrillation is the most frequent arrhythmia found in clinical practice. Atrial fibrillation doubles mortality and increases the risk of stroke. The early appearance of electrical remodeling is followed by structural remodeling of the atrial tissue. In the past decade, arrhythmologists have been encouraged to investigate the etiology and pathophysiology of this type of frequent arrhythmia. These investigations have resulted in new concepts on the initiation and perpetuation of this arrhythmia. New techniques are being developed for its treatment. However, the majority of patients are candidates for the traditional treatment: antiarrhythmic drugs and/or electrical cardioversion. Direct current cardioversion of persistent atrial fibrillation is the most effective treatment for the restoration of sinus rhythm, but it may be hampered by a high percentage of recurrences. Many of the recurrences are probably the clinical consequence of electrical remodelling [1, 2], due to the changes in refractory period of atrial muscle and/or due to abnormal activity occurring inside the pulmonary veins. This could explain the drug-resistance of long-standing atrial fibrillation.

Keywords

Atrial Fibrillation Sinus Rhythm Angiotensin Converting Enzyme Inhibitor Antiarrhythmic Drug Persistent Atrial Fibrillation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Allessie MA (1998) Atrial electrophysiological remodeling: another vicious circle? J Cardiovasc Electrophysiol 9:1378–1393PubMedCrossRefGoogle Scholar
  2. 2.
    Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA, Begets AF (1995) A study in awake chronically instrumented goats. Circulation 92:1954–1968PubMedCrossRefGoogle Scholar
  3. 3.
    Pedersen OD, Bagger H, KØber L, Torp-Pedersen C (1999) Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100:376–380PubMedCrossRefGoogle Scholar
  4. 4.
    Fortuno MA, Ravassa S, Etayo JC, Diez J (1998) Overexpression of Bax protein and enhanced apoptosis in the left ventricle of spontaneously hypertensive rats. Effects of AT1 blockade with losartan. Hypertension 32:280–286PubMedCrossRefGoogle Scholar
  5. 5.
    Nakashima H, Kumagai K, Urata H et al (2000) Angiotensin II Antagonist Prevents Electrical Remodeling in Atrial Fibrillation. Circulation 101:2612–2617PubMedCrossRefGoogle Scholar
  6. 6.
    LÓpez B, Querejeta R, Varo N et al (2001) Usefulness of serum carboxy-terminal pro-peptide of procollagen type I in assessment of the cardioreparative ability of antihy-pertensive treatment in hypertensive patients. Circulation 104: 286–291PubMedCrossRefGoogle Scholar
  7. 7.
    Madrid AH, Bueno MG, Rebollo JM et al (2002) Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation, a prospective and randomized study. Circulation 106:331–336PubMedCrossRefGoogle Scholar
  8. 8.
    Roy D, Talajic M, Dorian P et al (2000) Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342(13):913–920PubMedCrossRefGoogle Scholar
  9. 9.
    Kochiadakis GE, Igoumenidis NE, Marketou ME et al (1998) Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 81:995–998PubMedCrossRefGoogle Scholar
  10. 10.
    Kühlkamp V, Schirdewan A, Stangl K et al (2000) Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. J Am Coll Cardiol 36:139–146PubMedCrossRefGoogle Scholar
  11. 11.
    Crijns HJGM, Van Noord T, Van Gelder IC (2001) Recurrence of atrial fibrillation and the need for new definitions. Eur Heart J 22:1769–1771PubMedCrossRefGoogle Scholar
  12. 12.
    Caballero R, Delpön E, Valenzuela C et al (2002) Losartan and its metabolite E3174 modify cardiac delayed rectifier K+ currents. Circulation 101:1199–1205CrossRefGoogle Scholar
  13. 13.
    Moreno I, Caballero R, Gonzalez T et al (2003) Effects of irbersartan on cloned potassium channels involved in human cardiac repolarization. J Pharmacol Exp Ther:304Google Scholar
  14. 14.
    Wyse DG, Waldo AL, DiMarco JP et al (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347(23):1825–1833PubMedCrossRefGoogle Scholar
  15. 15.
    Van Gelder IC, Hagens VE, Bosker HA et al (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347(23):1834–1840PubMedCrossRefGoogle Scholar
  16. 16.
    Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC (1990) Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 82(4):1106–1116PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2004

Authors and Affiliations

  • A. H. Madrid
    • 1
  • C. Escobar
    • 1
  • J. M. G. Rebollo
    • 1
  • I. Marin
    • 1
  • E. Bernal
    • 1
  • L. Limón
    • 1
  • S. Nannini
    • 1
  • J. Peng
    • 1
  • C. Moro
    • 1
  1. 1.Arrhythmia Unit, Ramón y Cajal Hospital, Department of MedicineAlcalá UniversityMadridSpain

Personalised recommendations